PTCL represents a group of prototypical epigenetic malignancies with an invariably poor prognosis.[63] Epigenetic modifying agents, including histone deacetylase (HDAC) inhibitors such as chidamide, have demonstrated broad clinical efficacy and durability in PTCL and are being clinically developed as combination strategies in both relapse and frontline settings.[64, 65, 66] Given the effect of quinacrine on FACT inhibition, we hypothesized that quinacrine may further potentiate the effect of HDAC inhibitors. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.